-
Compass Therapeutics Shares Regulatory Update on Tovecimig for Biliary Tract Cancer
NASDAQ: $CMPX A New Path Forward Compass Therapeutics has recently provided a significant update regarding their clinical development program for tovecimig, an investigational therapy targeting biliary tract cancer. Following interactions with the U.S. Food and Drug Administration (FDA), the company is clarifying its regulatory strategy to move this treatment forward efficiently. Understanding the Regulatory Landscape…